Real-world phenotyping and risk assessment of childhood asthma burden using national registries
In a complete case analysis, 85.8 % children had at least one T2 risk factor and 29.3 % had mixed T2/non-T2 risk factors. Elevated blood eosinophils and total/specific IgE were associated with exacerbations (ORs 1.55 (1.38-1.73) and 1.41 (1.20-1.66) and higher asthma severity (1.42 (1.24-1.63) and 1.31 (1.08-1.60)), respectively. Dose-dependency was observed between blood eosinophil counts, total IgE levels, and risk of adverse outcomes. Furthermore, accumulation of risk factors demonstrated an increasing risk, with children with all four risk factors having a high risk of any adverse asthma-related outcome (OR 3.13 (2.03-4.82) CONCLUSION: Asthma phenotypic markers defined in research protocols can be reliably applied in real-world settings by utilizing data collected during routine clinical care and enable better classification of risk of adverse asthma outcomes.
Authors
- Silvia Cabrera Guerrero
- Deepa Rastogi (ORCID: https://orcid.org/0000-0001-5714-9250)
- Charlotte Suppli Ulrik (ORCID: https://orcid.org/0000-0001-8689-3695)
- Kjell Erik Julius Håkansson (ORCID: https://orcid.org/0000-0001-5804-0740)
- Nada Alabdulkarim (ORCID: https://orcid.org/0000-0001-9657-8058)
- Vibeke Backer (ORCID: https://orcid.org/0000-0002-7806-7219)
Institutions
- Albert Einstein College of Medicine (US)
- Mercy Health System (US)
- Children's National (US)
- Hvidovre Hospital (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Mercy Health (US)
Publication Details
- Journal
- Respiratory Medicine
- Published
- 2024-09-14
- DOI
- https://doi.org/10.1016/j.rmed.2024.107808
- Citations
- 1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.33
Funders
- Pfizer
- AstraZeneca
- Sanofi
- Teva Pharmaceutical Industries
- Covis Pharma
- Hvidovre Hospital
- Sanofi Genzyme